| Literature DB >> 35800845 |
Zachary A Creech1, Gia Thinh D Truong1, Dorothy X Kenny2, Dua Noor Butt3, Changzhao Li4, Stephen Cavalieri4, Rima El-Herte3.
Abstract
Freshwater-related infections can be caused by a broad range of pathogens, potentially leading to skin and soft tissue, pulmonary, gastrointestinal, or even systemic diseases. Haematospirillum jordaniae (H. jordaniae),a gram-negative, aerobic organism previously regarded solely as an environmental microbe, has been classified as a pathogen capable of causing human infection in the United States. There has been only one other case reported in the literature of H. jordaniae infection, and little is known about the pathogenesis.The presentation and progression of clinical symptoms in our cases indicate freshwater cutaneous injury as the most likely route of H. jordaniae infection. We present two cases of H. jordaniae infection in elderly males. Both patients had freshwater exposure and skin injury resulting in sepsis, cellulitis at the site of injury, and bacteremia. Additionally, one patient presented with an acute deep venous thrombosis. The diagnosis of H. jordaniae was confirmed using Sanger sequencing 16s ribosomal RNA data. Antimicrobial therapy included piperacillin-tazobactam, ceftazidime, and levofloxacin. Both patients recovered successfully. While clinical cases and literature involving the newly classified human pathogen H. jordaniae are still rare, it is crucial to recognize the potential emergence of environmental organisms, previously believed to be harmless, as human pathogens. In cases of bacteremia and cellulitis with recent freshwater exposure and injury, H. jordaniae infection should be considered as part of the differential diagnosis.Entities:
Keywords: bacteremia; cellulitis; freshwater; haematospirillum jordaniae; infectious disease
Year: 2022 PMID: 35800845 PMCID: PMC9246461 DOI: 10.7759/cureus.25480
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1The leg of patient 1 at admission
Images show left leg examination upon admission (A) and after three days (B).
Laboratory values of patient 1 at the time of admission
| Laboratory value (units) | Patient 1 | Normal reference values |
| White blood cell count (WBCs/μL) | 13,700 | 4,500-11,000 |
| Neutrophil count (neutrophils/μL) | 10,800 | 1,500-8,000 |
| Albumin (g/dL) | 3 | 3.5-5 |
| Calcium (mg/dL) | 8.3 | 8.5-10.5 |
| AST (U/L) | 14 | 10-45 |
| ALT (U/L) | 21 | 9-44 |
| Anion gap (mmol/L) | 8 | <20 |
| Blood urea nitrogen (mg/dL) | 16 | 7-18 |
| Creatinine (mg/dL) | 1.09 | 0.6-1.2 |
| Sodium (mmol/L) | 140 | 137-145 |
| Potassium (mmol/L) | 4.1 | 3.7-5.1 |
| Chloride (mmol/L) | 110 | 96-110 |
| Platelets (platelets/μL) | 155,000 | 140-44,000 |
| Serum glucose (mg/dL) | 104 | 70-100 |
| Hemoglobin (g/dL) | 14.5 | 13.5-17.5 |
| Calculated GFR MDRD non-African American (mL/minute/1.73 m2) | 71 | ≥90 |
Figure 2Treatment progression of the first patient
The image depicts the first patient’s left leg after 26 days of treatment.
Laboratory values of patient 2 at admission
| Laboratory value (units) | Patient 2 | Normal reference values |
| White blood cell count (WBCs/μL) | 20,800 | 4,500-11,000 |
| Neutrophil count (neutrophils/μL) | 17,900 | 1,500-8,000 |
| Calcium (mg/dL) | 9.1 | 8.5-10.5 |
| Anion gap (mmol/L) | 9 | <20 |
| Blood urea nitrogen (mg/dL) | 30 | 7-18 |
| Creatinine (mg/dL) | 1.48 | 0.6-1.2 |
| Sodium (mmol/L) | 139 | 137-145 |
| Potassium (mmol/L) | 3.8 | 3.7-5.1 |
| Chloride (mmol/L) | 108 | 96-110 |
| Platelets (platelets/μL) | 192,000 | 140-44,000 |
| Serum glucose (mg/dL) | 191 | 70-100 |
| Hemoglobin (g/dL) | 14.3 | 13.5-17.5 |
| Calculated GFR MDRD non-African American (mL/minute/1.73 m2) | 47 | ≥90 |
Figure 3Growth patterns in variable media
Pictures show bacteria growth on blood agar (A), but not on MacConkey (B) and chocolate agar (C).
Figure 4Gram stain showing abundant gram-negative rods
The staining depicts faintly stained bacteria in the background.
Figure 5Oxidase test results
The blue color indicates a positive oxidase biochemical reaction.
Figure 6Etest results
Ceftazidime Etest shows an MIC of 4 μg/mL.